SLC5A2 and heart failure: In recent cardiovascular outcome trials, SGLT2 inhibitors are associated with 30%–35% lower risk of hospitalisation for heart failure.9–12 Other glucose-lowering agents appear to be more potent than SGLT2 inhibitors, but fail to reduce cardiovascular risk, particularly with regard to heart failure outcomes.